TNF-alpha antagonists and LFA-1 antagonist for treating LFA-1 or TNF-alpha mediated disorder

摘要

Disclosed are compositions comprising effective amounts of an LFA-1 antagonist and a TNF- alpha antagonist. Such compositions are useful in methods for the treatment of an LFA-1 mediated disorder or a TNF- alpha mediated disorder, including cartilage damage, degenerative cartilaginous disorders like rheumatoid arthritis, juvenile chronic arthritis and osteoarthritis, spondyloarthropathy, psoriasis, systemic lupus erythematosus, multiple sclerosis, diabetes, asthma, uveitis and inflammatory bowel disease, particularly Crohn's disease.